Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
- Nucala Filed in Japan for Chronic Rhinosinusitis with Nasal Polyps: GSK
September 5, 2023
- Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
- Otsuka to Acquire Canada’s Psychedelic Specialist Mindset Pharma
September 4, 2023
- Enhertu Gets 2 More Breakthrough Therapy Tags in US: Daiichi Sankyo
September 4, 2023
- Shionogi Wins SCARDA R&D Funding for Nasal Vaccines for Flu, COVID
September 1, 2023
- Atozet Generic to Hit Japan Shelves on Sept. 1
September 1, 2023
- Ono, Twist Bio Tie Up on Antibody Discovery for Autoimmune Disorders
September 1, 2023
- 2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
September 1, 2023
- Sobi’s PNH Drug to Hit Japan Market on Sept. 4, Taiho's FGFR Inhibitor on Sept. 7
August 31, 2023
- Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
- Sandoz Completes Acquisition of Astellas’ Antifungal Mycamine
August 31, 2023
- Toray to Kick Off Antibody PII Studies for Gastric Cancer
August 31, 2023
- Takeda Snags Japan Rights to ImmunoGen’s ADC
August 30, 2023
- Shionogi Rolls Out Flomox Fine Granules for Children in China
August 30, 2023
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Oral Flu Drug Prescriptions 11 Times More than Pre-COVID: July Survey
August 29, 2023
- Nichi-Iko Winds Up Avastin Biosimilar Deal with Sandoz
August 29, 2023
- Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
August 29, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…